2024 Partners


Expertise Partner

We have developed novel technology that generates, collects, structures, and analyzes vast amounts of data and merged with the power of AI, we can advance precision medicine today, and in parallel, facilitate discovery, development and delivery of optimal therapeutics for tomorrow.


Lide Logo

Expertise Partner

LIDE is an award-winning oncology contract research organization with 12 years of delivering drug evaluation services to 200+ clients worldwide. We offer traditional preclinical CRO services like pharmacology, PK, and biomarker studies with 70+ CDX models and 2000 patient-derived xenograft (PDX) models. Our library covers 50+ cancer types and 200+ models harbor special naturally-occurred drug-resistant and/or genetic alterations. Ask us about our proprietary tools for in-vivo drug validation in 7-10 days.



Expertise Partner

GemPharmatech Co., Ltd. is a leading company in China to provide high-quality animal model resources and services for biomedical community as well as pharmaceutical companies. Based on more than 16 years’ practice in laboratory animals of the former entity, GemPharmatech has the vision and is striving to become one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners all across the world.


certis-logo-lockup-CMYK (002)

Expertise Partner

Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.



Expertise Partner

Kiyatec is a functional precision oncology company that accurately measures the response of each patient’s live cancer cells to aid in drug development and inform clinical treatment decisions. The company works in partnership with leading biopharmaceutical companies to unlock response dynamics for their pre-clinical investigational drug candidates across most solid tumor types. Kiyatec’s CLIA- certified labs offer clinical testing for high-grade glioma, and is developing assays for use in ovarian, breast, NSCLC, and rare tumors.


XenoStart_Final Logo Files_All

Expertise Partner

XenoSTART is a global nonclinical oncology contract research organization focused on the development and utilization of patient-derived xenograft models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organization. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models.

​Our XPDX models are clinically annotated and include patient treatment history and outcome and are characterized through genomic profiling, histologic analysis, and in vivo drug sensitivity to relevant standards of care.


Charles River

Program Partner

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.



Program Partner

We are your scientifically-driven and flexible partner for drug development. Our team is fully dedicated to oncology – it is all we do – combining innovation and expertise to quickly move your therapies from preclinical development into clinical trials. Adaptive and forward-thinking – we guide your therapy through the most critical development milestones from the lab to planning your regulatory and clinical strategy and ultimately approved.



Program Partner

ChemPartner is a CRO provider with 20 years of experience supporting drug discovery and development from concept to IND, with a focus on oncology, immunology, and CNS disease. Our oncology team offers >2,000 biochemistry assays, >800 cancer cell lines for screening and functional assays, >300 CDX and >50 syngeneic models at both subcutaneous and orthotopic settings, as well as >500 PDX. Additionally, ChemPartner has a fully equipped suite of ex vivo capabilities, such as flow, MSD, and IHC.



Program Partner

Mission Bio specializes in the widespread adoption of single-cell DNA and multi-omic analysis. The Tapestri Platform, enabled by Pharma Assay Development services for pharma companies, is propelling advancements in cancer research, drug development, and cell and gene therapy, where understanding genetic heterogeneity at the single-cell level is crucial. This technology has the potential to lead to more personalized and effective treatment strategies. The level of precision and resolution provided is not easily achievable with traditional methods.



Exhibition Partner



Exhibition Partner

Studylog (Company bio - Studylog’s Animal Study Workflow Software® is designed for biomedical animal research and provides features for the design, planning, execution, analysis, and reporting of animal studies in a standardized, highly efficient manner, while protecting data integrity. Reducing many labs’ study-related labor by half, Studylog automates and streamlines the entire animal study process, making it easier, faster and cheaper, so researchers have more time and resources to get their job done.



Exhibition Partner

At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development lifecycle.

From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.



Exhibition Partner

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients.

WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.